Identification of a cytokine-dominated immunosuppressive class in squamous cell lung carcinoma with implications for immunotherapy resistance

BACKGROUND: Immune checkpoint blockade (ICB) therapy has revolutionized the treatment of lung squamous cell carcinoma (LUSC). However, a significant proportion of patients with high tumour PD-L1 expression remain resistant to immune checkpoint inhibitors. To understand the underlying resistance mech...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Minglei, Lin, Chenghao, Wang, Yanni, Chen, Kang, Zhang, Haiyue, Li, Weizhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264601/
https://www.ncbi.nlm.nih.gov/pubmed/35799269
http://dx.doi.org/10.1186/s13073-022-01079-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264601/
https://www.ncbi.nlm.nih.gov/pubmed/35799269
http://dx.doi.org/10.1186/s13073-022-01079-x

Ejemplares similares